Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
854 results about "Bioactive molecules" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bioactive molecules are substance that can be acted upon by a living organism or by an extract from a living organism. These molecules especially glycosaminoglycans(a polysaccharides) have therapeutic potential.
Citric acid polymers
InactiveUS20090325859A1Peptide/protein ingredientsGenetic material ingredientsPoly(ethylene glycol) dimethyl etherPolyethylene glycol
The present invention provides polymers (e.g., elastomeric citric acid polymers) and methods of making and using these polymers (e.g., as a biologically active molecule delivery platform). In certain embodiments, the polymer has adsorbed biologically active molecules. In particular embodiments, the polymer comprises pores that are between about 7 and 15 nanometers in diameter. In other embodiments, the polymer comprises poly(1,8 octanediol-co-ctric acid). In certain embodiments, the polymers are made by employing polyethylene glycol dimethyl ether (PEGDM).
Owner:NORTHWESTERN UNIV
Post-partum mammalian placenta, its use and placental stem cells therefrom
InactiveUS20030032179A1Enhance exsanguinationEnhance sterile conditionSenses disorderAntipyreticAnticoagulant AgentEmbryo
The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.
Owner:CELULARITY INC
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
ActiveUS7404969B2Reduce deliveryAntibacterial agentsOrganic active ingredientsLipid formationMolecular composition
The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver short interfering nucleic acid (siNA). The compositions described herein are generally referred to as formulated molecular compositions (FMC) or lipid nanoparticles (LNP).
Owner:SIRNA THERAPEUTICS INC
Method of collecting placental stem cells
InactiveUS20020123141A1Increase concentrationImprove the environmentSenses disorderAntipyreticCord blood stem cellEmbryo
A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.
Owner:CELULARITY INC
Methods for chemically synthesizing immunoglobulin chimeric proteins
ActiveUS7381408B2Prolong lifeEasy to purifyHydrolasesPeptide/protein ingredientsChimera ProteinBiochemistry
The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.
Owner:BIOVERATIV THERAPEUTICS INC
Serum albumin binding peptides for tumor targeting
InactiveUS20050287153A1Altered pharmacodynamicsFacilitated DiffusionImmunoglobulins against blood coagulation factorsImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal tissue growthPeptide ligand
Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.
Owner:GENENTECH INC
Post-partum mammalian placenta, its use and placental stem cells therefrom
The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.
Owner:CELULARITY INC
Bioactive coating composition and methods
InactiveUS6921811B2Promotes desired biologicalPromotes therapeutic effectSuture equipmentsOrganic active ingredientsArylBody fluid
The present invention provides a bioactive coating composition, method and devices for bodily fluid-contacting surfaces. The coating comprises a complex of Formula II: wherein R1 is an C1-18alkyl or C6-32aryl group, each R2 is independently selected from the group consisting of C1-18alkyl and C6-32aryl, R3 is N or O, n is a number from 1 to 10, and x in a number from 1 to about 30, directly bound to a heparin-activity molecule via covalent bonding, with one or more bioactive molecules bound to the heparin-activity molecule. The bioactive molecule may be an adhesive molecule such as fibronectin, a growth factor such as basic fibroblast growth factor, or any other bioactive molecule that binds, by any mechanism, to a heparin-activity molecule
Owner:BIOSURFACE ENG TECH
PUFA polyketide synthase systems and uses thereof
The invention generally relates to polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems, to homologues thereof, to isolated nucleic acid molecules and recombinant nucleic acid molecules encoding biologically active domains of such a PUFA PKS system, to genetically modified organisms comprising PUFA PKS systems, to methods of making and using such systems for the production of bioactive molecules of interest, and to novel methods for identifying new bacterial and non-bacterial microorganisms having such a PUFA PKS system.
Owner:DSM IP ASSETS BV
PUFA polyketide synthase systems and uses thereof
InactiveUS7271315B2BryophytesOther foreign material introduction processesLipid formationBiotechnology
Disclosed are the complete polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems from Schizochytrium, and biologically active fragments and homologues thereof. More particularly, this invention relates to nucleic acids encoding such PUFA PKS systems, to proteins and domains thereof that comprise such PUFA PKS systems, to genetically modified organisms (plants and microorganisms) comprising such PUFA PKS systems, and to methods of making and using the PUFA PKS systems disclosed herein. This invention also relates to genetically modified plants and microorganisms and methods to efficiently produce lipids enriched in various polyunsaturated fatty acids (PUFAs) as well as other bioactive molecules by manipulation of a PUFA polyketide synthase (PKS) system.
Owner:DSM IP ASSETS BV
Interactive psychophysiological profiler method and system
An efficient, objective, flexible and easily deployable system for conducting evaluations of mental and physiological state and recommending individualized treatment to improve said state is described. The method and system are based on commensurate measurement of mental functions, levels of stress and anxiety, and / or biologically active molecules such as neurotransmitters, immune markers including cytokines and hormones. The method and system are designed to assess an individual's cognitive function and the underlying physiology in order to delineate various disease processes, injuries, drug states, training stages, fatigue levels, stress levels, aging processes, predict susceptibility to stress and / or sleep deprivation, identify aptitude for training and / or characterize effects of any experimental conditions. The system and method may be used in recommending individualized treatment protocols, as well as to guide the treatment process by assessing the efficacy of such therapies in the clinical trials process.
Owner:ADVANCED BRAIN MONITORING
PUFA polyketide synthase systems and uses thereof
Disclosed are the complete polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems from the bacterial microorganisms Shewanella japonica and Shewanella olleyana, and biologically active fragments and homologues thereof. More particularly, this invention relates to nucleic acids encoding such PUFA PKS systems, to proteins and domains thereof that comprise such PUFA PKS systems, to genetically modified organisms (plants and microorganisms) comprising such PUFA PKS systems, and to methods of making and using the PUFA PKS systems disclosed herein. This invention also relates to genetically modified plants and microorganisms and methods to efficiently produce lipids enriched in various polyunsaturated fatty acids (PUFAs) as well as other bioactive molecules by manipulation of a PUFA polyketide synthase (PKS) system.
Owner:DSM IP ASSETS BV
Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Pegylated nanoparticles
ActiveUS8628801B2Good bioadhesionStrong specificityPowder deliveryCosmetic preparationsZeta potentialOrganic synthesis
Owner:INNOUP FARMA
Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
InactiveUS20060275371A1Poor cellular uptakeReduced bioavailabilityOrganic active ingredientsBiocideEndosomal membraneNanoparticle
Methods and materials for delivering biologically active molecules to cells in vitro or in vivo are provided. The methods and materials use carbon nanotubes or other hydrophobic particles, tubes and wires, functionalized with a linking group that is covalently bound to the nanotubes, or, alternatively, to the biologically active molecule, such as a protein. The biologically active molecule is preferably released from the nanotube when the complex has been taken up in an endosome.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Multifunctional and biologically active matrices from multicomponent polymeric solutions
The present invention relates to a biologically active functionalized electrospun matrix to permit immobilization and long-term delivery of biologically active agents. In particular the invention relates to a functionalized polymer matrix comprising a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized with low molecular weight heparin. Examples of active molecules that may be used with the multicomponent polymer of the invention include, for example, a drug, a biopolymer, for example a growth factor, a protein, a peptide, a nucleotide, a polysaccharide, a biological macromolecule or the like. The invention is further directed to the formation of functionalized crosslinked matrices, such as hydrogels, that include at least one functionalized compatibilizing polymer capable of assembly.
Owner:UNIVERSITY OF DELAWARE
Methods and compositions related to the modulation of intercellular junctions
InactiveUS20060067927A1Good cell permeabilityReduce deliveryBiocideOrganic active ingredientsPolysaccharideRectal epithelium
The invention relates to compositions and methods for the modulation of the permeability of the epithelial cell barrier complex. In particular, the invention provides compositions and methods for using polysaccharides, preferably glycosaminoglycans, and agents that modify cell surface glycosaminoglycans, preferably glycosaminoglycan-degrading enzymes to modulate intercellular junctions. The compositions and methods provided can be used to facilitate the delivery of biologically active molecules.
Owner:MASSACHUSETTS INST OF TECH
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
A poly(ethylene glycol) derivative is disclosed that is activated with a sulfone moiety for selective attachment to thiol moieties on molecules and surfaces. The activated PEG is water soluble, hydrolytically stable for extended periods, and forms hydrolytically stable linkages with thiol moieties. The linkages generally are not reversible in reducing environments. The PEG derivative is useful for modifying the characteristics of substances including modifying biologically active molecules and surfaces for biocompatibility. Methods for synthesizing the active PEG and for preparing conjugates of the active PEG and other substances, including biologically active substances, are also disclosed.
Owner:NEKTAR THERAPEUTICS INC
Magnetically-responsive microspheres
InactiveUS6773812B2Easy to doNanomagnetismSynthetic resin layered productsMicrosphereMagnetite Nanoparticles
Microspheres are constructed using magnetic particles. Hybrid microspheres are constructed using fluorescent or luminescent microspheres and magnetic nanoparticles. Reactive moieties on the surface of the resultant particles can be used for attachment of biologically active molecules, thus allowing selective separations and analytical assays to be performed. Distinguishable subsets of microspheres can be constructed based on fluorescent intensities, and separations can be affected based on variable degree of magnetic content.
Owner:LUMINEX
Polyamine Derivatives
ActiveUS20100260817A1Improve efficiencyImproving of local deliveryOrganic active ingredientsSenses disorderWhole bodyMedicinal chemistry
Owner:CLSN LAB
Compounds and methods for reversible modification of biologically active molecules
The present invention is directed compounds for reversibly modification of biologically active molecules. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
Owner:ARROWHEAD MADISON
Localized non-invasive biological modulation system
The present invention provides methods for non-invasive localized delivery of biologically active molecules, comprising packaging a molecule(s) of interest inside a thermosensitive particle, administering said particles to a subject, and inducing localized release of said molecules from said particles using a focused heat source. The thermosensitive particles may be thermosensitive polymer nanoparticles or thermosensitive liposomes. The particles may be delivered to a subject by any technique, including infusion. The molecules may be released from the particles using any method which induces localized hyperthermia, including focused ultrasound.
Owner:SAOIRSE CORP
Polyamine derivatives
ActiveUS8460696B2Reduce deliveryImprove efficiencyOrganic active ingredientsSenses disorderMedicinal chemistryPolyamine
Owner:CLSN LAB
Non-invasive measurement of analytes
ActiveUS20070020181A1Efficiently determinedGreat simplicityMicrobiological testing/measurementChemiluminescene/bioluminescenceBiological bodyMetabolite
This invention provides devices, compositions and methods for determining the concentration of one or more metabolites or analytes in a biological sample, including cells, tissues, organs, organisms, and biological fluids. In particular, this invention provides materials, apparatuses, and methods for several non-invasive techniques for the determination of in vivo blood glucose concentration levels based upon the in vivo measurement of one or more biologically active molecules found in skin.
Owner:CERCACOR LAB INC
Immunoglobulin fusion proteins
ActiveUS7867491B2Extended half-lifeImprove expression levelPeptide/protein ingredientsAntipyreticFc domainBioactive molecules
Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.
Owner:POSTECH ACADEMY IND FOUND OF POHANG UNIV OF SCI & TECH POSTECH +1
Non-stochastic generation of genetic vaccines and enzymes
InactiveUS6713279B1Improve abilitiesPotent and direct effect on proliferation and Ig-synthesisAnimal cellsHydrolasesAntigenBiological property
This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by use of non-stochastic methods of directed evolution (DirectEvolution(TM)). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis(TM)) and non-stochastic polynucleotide reassembly (GeneReassembly(TM)). Through use of the claimed methods, genetic vaccines, enzymes, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. This invention provides methods of obtaining novel enzymes that have optimized physical & / or biological properties. Furthermore, this invention provides methods of obtaining a variety of novel biologically active molecules, in the fields of antibiotics, pharmacotherapeutics, and transgenic traits.
Owner:BP CORP NORTH AMERICA INC
Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases
Synergistic chemical compositions of bioactive compounds in a dietary supplement for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases; chemical compositions of a sugar free super sweetener for people with Type-2 Diabetes disease and a targeted nano delivery of bioactive compounds and / or bioactive molecules are described. Furthermore, microelectro-mechanical system (Mems) based passive and active (based on feedback diagnostics data) delivery systems and methods of bioactive compounds and / or bioactive molecules are also described.
Owner:MAZED MOHAMMAD A +1
Buffer solution for electroporation and a method comprising the use of the same
InactiveUS20050064596A1High transfection efficiencyReduce cell deathPeptide/protein ingredientsGenetic material ingredientsElectroporationIon
The invention relates to a buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce said biologically active molecules into the cells using an electric current and to a method for introducing biologically active molecules into animal or human cells using an electric current and a buffer solution. The inventive buffer solution has a buffering capacity of at least 20 mmol*I−1*pH−1 and an ionic strength of at least 200 mmol*I−1 during a change to the pH value from pH 7 to pH 8 and at a temperature of 25° C. The use of a buffer solution of this type in the corresponding method allows biologically active molecules to be introduced into animal and human cells with a high degree of transfection efficiency and at the same time a low cell mortality. Different cell types, in particular dormant and actively dividing cells of low activity, can be successfully transfected in said buffer solution.
Owner:LONZA COLOGNE
Chemical Compositon And Its Devlivery For Lowering The Risks Of Alzheimer's Cardiovascular And Type -2 Diabetes Diseases
ActiveUS20160004298A1Reduce riskInput/output for user-computer interactionTelevision system detailsThe InternetBiomarker (petroleum)
Chemical compositions of bioactive compounds and / or bioactive molecules for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases are described. Targeted, passive and programmable / active deliveries of the bioactive compounds and / or bioactive molecules are described. Many embodiments of various subsystems for detection of disease specific biomarkers / an array of disease specific biomarkers and programmable / active delivery of the bioactive compounds and / or bioactive molecules in near real-time / real-time are also described. A portable internet appliance, a portable internet cloud appliance and an augmented reality personal assistant subsystem are also described along with various applications.
Owner:MAZED MOHAMMAD A +1
Method for preparing polymeric biomaterials having immobilized drug delivery system comprising bioactive molecules loaded particle carrier
InactiveUS20130045266A1Improve low histocompatibilityGood wound healing effectAntibacterial agentsImpression capsMedicineWound site
A new polymeric material for biological tissue regeneration or treatment with a drug delivery system which contains therapeutic agents and / or bioactive molecules to reduce infection and inflammatory reaction at a wound site and maximize tissue regeneration and wound healing is provided. The new bioactive molecule-loaded polymeric material is prepared by (1) preparing micrometer or nanometer sized bioactive molecule-loaded particles; (2) modifying the surface of the prepared particles and immobilizing the particles on the surface of the polymeric material; and (3) physically treating the surface of the polymeric material to improve binding strength of the particles immobilized thereon.
Owner:CHUNGBUK NAT UNIV IND ACADEMIC COOPERATION FOUND +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com